全文获取类型
收费全文 | 45527篇 |
免费 | 2224篇 |
国内免费 | 172篇 |
专业分类
耳鼻咽喉 | 661篇 |
儿科学 | 1101篇 |
妇产科学 | 970篇 |
基础医学 | 5930篇 |
口腔科学 | 3736篇 |
临床医学 | 2826篇 |
内科学 | 10449篇 |
皮肤病学 | 1265篇 |
神经病学 | 4095篇 |
特种医学 | 981篇 |
外国民族医学 | 1篇 |
外科学 | 5416篇 |
综合类 | 231篇 |
一般理论 | 11篇 |
预防医学 | 4027篇 |
眼科学 | 1111篇 |
药学 | 3226篇 |
中国医学 | 323篇 |
肿瘤学 | 1563篇 |
出版年
2023年 | 393篇 |
2022年 | 859篇 |
2021年 | 1648篇 |
2020年 | 927篇 |
2019年 | 1365篇 |
2018年 | 1748篇 |
2017年 | 1119篇 |
2016年 | 1208篇 |
2015年 | 1436篇 |
2014年 | 1902篇 |
2013年 | 2357篇 |
2012年 | 3610篇 |
2011年 | 3945篇 |
2010年 | 2053篇 |
2009年 | 1635篇 |
2008年 | 2902篇 |
2007年 | 2823篇 |
2006年 | 2504篇 |
2005年 | 2259篇 |
2004年 | 2089篇 |
2003年 | 1734篇 |
2002年 | 1591篇 |
2001年 | 854篇 |
2000年 | 863篇 |
1999年 | 689篇 |
1998年 | 240篇 |
1997年 | 153篇 |
1996年 | 145篇 |
1995年 | 110篇 |
1994年 | 123篇 |
1993年 | 87篇 |
1992年 | 251篇 |
1991年 | 250篇 |
1990年 | 217篇 |
1989年 | 174篇 |
1988年 | 180篇 |
1987年 | 159篇 |
1986年 | 122篇 |
1985年 | 119篇 |
1984年 | 99篇 |
1983年 | 92篇 |
1982年 | 41篇 |
1981年 | 47篇 |
1980年 | 47篇 |
1979年 | 74篇 |
1978年 | 60篇 |
1975年 | 45篇 |
1973年 | 43篇 |
1971年 | 51篇 |
1967年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
941.
P.M. Martínez Pérez-Crespo L.E. López-Cortés P. Retamar-Gentil J.F. Lanz García D. Vinuesa García E. León J.M. Sánchez Calvo F. Galán-Sánchez C. Natera Kindelan A. del Arco Jiménez A. Sánchez-Porto C. Herrero Rodríguez B. Becerril Carral I.M. Reche Molina J.M. Reguera Iglesias I. Pérez Camacho M. Guzman García I. López-Hernández J. Rodríguez-Baño 《Clinical microbiology and infection》2021,27(2):283.e9-283.e16
ObjectivesDuring the last decade, some changes in the epidemiology of invasive infections have been reported; however, specific studies with patient-level data are scarce. The aim of this study was to describe and evaluate the epidemiologic changes in bloodstream infections (BSI) during the last decade in Andalucía, Spain.MethodsData from two prospective cohorts of BSI in adults with the same methodology performed 10 years apart in 11 hospitals (eight tertiary and three community) in Andalucía, Spain, were compared; the 2006–7 cohort study was performed between October 2006 and March 2007, and the 2016–17 cohort study was performed between October 2016 and March 2017. Population-based incidence rates were calculated and extrapolated for 1 year. Relative risk ratios were calculated between the 2 periods. Multivariate analyses were performed by logistic regression.ResultsOverall, 1262 episodes of BSI were included, 563 (44.6%) in 2006–7 and 699 (55.3%) in 2016–17. Multivariate models selected the following changes in patients' features in 2016–17, after controlling for type of acquisition: higher age (odds ratio (OR) = 1.02; 95% confidence interval [CI] 1.01–1.03), lower urinary catheter (OR = 0.37; 95% CI, 0.26–0.48) and lower Pitt score (OR = 0.76; 95% CI, 0.71–0.82). Adjusted estimations considering patients' features and exposure to procedures showed a reduction in coagulase-negative staphylococci (OR = 0.47; 95% CI, 0.32–0.69), and an increase in Proteus spp. (OR = 3.12; 95% CI, 1.18–8.23) and Candida spp. (OR = 3.01; 95% CI, 1.03–8.86).ConclusionsWe found relevant epidemiologic changes in BSI in our area, including rates, frequency of acquisition types, changes in patient's profiles and aetiologic agents. 相似文献
942.
Jesús Rodríguez-Baño Jerónimo Pachón Jordi Carratalà Pablo Ryan Inmaculada Jarrín María Yllescas José Ramón Arribas Juan Berenguer 《Clinical microbiology and infection》2021,27(2):244-252
ObjectivesThe objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters.MethodsA cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs).ResultsIn all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22–0.47; p < 0.001) for tocilizumab, 0.82 (0.71–1.30; p 0.82) for IHDC, 0.61 (0.43–0.86; p 0.006) for PDC, and 1.17 (0.86–1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02–0.17; p < 0.001).ConclusionsTocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situation. 相似文献
943.
944.
Dafne D.G. Horovitz Emília K.E.A. Leão Erlane M. Ribeiro Ana M. Martins Anneliese L. Barth João I.C.F. Neri Marcelo Kerstenetzky Ana C.M. Siqueira Bethania F.R. Ribeiro Chong A. Kim Francisca C. Santos José F.S. Franco Leniza C.L. Lichtvan Liane R. Giuliani Maria Do C.S. Rodrigues Renata C.F. Bonatti Thaís B. Teixeira Alexandra Gonçalves Angelina X. Acosta 《Molecular genetics and metabolism》2021,132(1):94-99
Patients with mucopolysaccharidosis type VI (MPS VI) present with a wide range of disease severity and clinical manifestations, with significant functional impairment and shortened lifespan. Enzyme replacement therapy (ERT) with galsulfase has been shown to improve clinical and biochemical parameters including patient survival, quality of life and growth. The present study is a resurvey of 34 Brazilian MPS VI patients with rapidly progressive disease (classical phenotype) who initiated ERT with galsulfase under five years of age and had been on ERT until data collection in 2019, with few exceptions (n = 4 patients who died before 2019).Anthropometric measures, urinary glycosaminoglycans, and data regarding cardiac, orthopedic, neurologic, sleep apnea, hearing and ophthalmologic outcomes were filled in by specialists. Pubertal development, clinical complications, hospitalizations, and surgeries were also assessed.In this resurvey study, treatment with galsulfase has shown to be safe and well tolerated in MPS VI patients who initiated ERT under the age of 5 years and who have been undergoing ERT for approximately 10 years. Mortality rate suggests that early initiation of ERT may have a positive impact on patients' survival, improving but not preventing disease progression and death. MPS VI patients on ERT also showed improved growth velocity and the pubertal development was normal in all surviving patients.Follow-up data on pneumonia and hospitalization suggest that early ERT may have a protective effect against major respiratory complications. Cardiac valve disease progressed since their prior evaluation and spinal cord compression was observed in a large number of patients, suggesting that these disease complications were not modified by ERT. 相似文献
945.
946.
947.
Rocío Seijo Bestilleiro Diana Martinez Searis María Jos Pereira Rodríguez Rita Galeiras Vzquez Raquel García Rodríguez María Teresa García Rodriguez Cristina Gonzlez Martín María Teresa Seoane Pillado Vanesa Balboa Barreiro Valentín Valds Valia Sonia Prtega Díaz 《International journal of medical sciences》2021,18(10):2146
948.
Brenda Stefany dos Santos Braga Dário Lisboa Fernandes-Neto Leonardo Conceição Teixeira Juliane da Silva Costa Maria Auxiliadora Pantoja Ferreira Verônica Regina Oliveira-Bahia José Ribamar Felipe Marques Diva Anelie de Araújo Guimarães 《Anatomical record (Hoboken, N.J. : 2007)》2021,304(6):1280-1293
The morphological study of limbs is important for the understanding of tetrapod biology, where it can be applied to taxonomy and phylogeny, as well ecology and behavior. In this study area, osteogenesis is a subject in Kinosternidae, which has been little researched. The main aim of this study was to characterize the skeletogenesis of Kinosternon scorpioides limbs. Samples were histologically processed, and the embryos were cleared with potassium hydroxide and stained with alcian blue and alizarin red. It was observed that the limbs arose in embryonic Stage 10 as mesenchymal condensate cells. The first stylopodium chondrification centers were noted at Stage 14. Zeugopodium chondrification centers appeared at Stage 15; carpal, metacarpal, tarsal, and metatarsal regions were observed at Stage 16, and the cartilage molds of all bones limbs were present at Stage 18. Ossification began in the humerus and femur at Stage 20, and continued into the radius, ulna, tibia, and fibula bones. By Stage 23, it was already effectively directed toward the bone epiphyses in both limbs. At Stage 26 and hatching, only articular cartilages remained, and in the majority of samples the carpal region showed no affinity for alcian blue or alizarin red staining. This study acts as an indicative parameter of the taxon's normal development and can contribute to the phylogenetic understanding of this group. 相似文献
949.
Angele Martins Claudia Koch Mitali Joshi Roberta Pinto Paulo Passos 《Anatomical record (Hoboken, N.J. : 2007)》2021,304(10):2149-2182